Mass spectrometry-based comparative sequence analysis for the genetic monitoring of influenza A(H1N1)pdm09 virus.
The pandemic influenza A (H1N1) 2009 virus (pH1N1) contains novel gene segments of zoonotic origin that lack virulence and antiviral resistance markers. We aimed to evaluate the applicability and accuracy of mass spectrometry-based comparative sequence analysis (MSCSA) to detect genetic mutations associated with increased virulence or antiviral resistance in pH1N1. During the 2009 H1N1 pandemic, routine surveillance specimens and clinical antiviral resistance monitoring specimens were analyzed. Routine surveillance specimens obtained from 70 patients with pH1N1 infection were evaluated for mutations associated with increased virulence (PB1-F2, PB2 and NS1 genes) or antiviral resistance (neuraminidase gene, NA) using MSCSA and Sanger sequencing. MSCSA and Sanger sequencing results revealed a high concordance (nucleotides >99%, SNPs ∼ 94%). Virulence or resistance markers were not detected in routine surveillance specimens: all identified SNPs encoded for silent mutations or non-relevant amino acid substitutions. In a second study population, the presence of H275Y oseltamivir resistant virus was identified by real-time PCR in 19 of 35 clinical antiviral resistance monitoring specimens obtained from 4 immunocompromised patients with ≥ 14 days prolonged pH1N1 excretion. MSCSA detected H275Y in 24% (4/19) of positive specimens and Sanger sequencing in 89% (17/19). MSCSA only detected H275Y when the mutation was dominant in the analyzed specimens. In conclusion, MSCSA may be used as a rapid screening tool during molecular surveillance of pH1N1. The low sensitivity for the detection of H275Y mutation in mixed viral populations suggests that MSCSA is not suitable for antiviral resistance monitoring in the clinical setting.
Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
Jairo
J
Gooskens
Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
Jessika C
JC
Zevenhoven-Dobbe
Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
Eric C
EC
Claas
Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
Aloys C M
AC
Kroes
Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
Clara C
CC
Posthuma
D000998:Antiviral Agents / Q000494:pharmacology; D024882:Drug Resistance, Viral / Q000235:genetics*; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000145:classification / Q000235:genetics* / Q000302:isolation & purification; D007251:Influenza, Human / Q000235:genetics* / Q000821:virology; D009154:Mutation / Q000235:genetics*; D009439:Neuraminidase / Q000235:genetics; D012324:RNA-Dependent RNA Polymerase / Q000235:genetics; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D017361:Viral Nonstructural Proteins / Q000235:genetics; D014764:Viral Proteins / Q000235:genetics*; D014774:Virulence / Q000235:genetics*
D000998:Antiviral Agents; C085820:INS1 protein, influenza virus; C442816:PB1-F2 protein, Influenza A virus; C057027:PB2 protein, Influenzavirus A; D017361:Viral Nonstructural Proteins; D014764:Viral Proteins; D012324:RNA-Dependent RNA Polymerase; D009439:Neuraminidase